MCRB [NASD]
Seres Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own9.01% Shs Outstand92.16M Perf Week-7.56%
Market Cap290.73M Forward P/E- EPS next Y-1.08 Insider Trans0.00% Shs Float83.92M Perf Month-37.02%
Income-86.70M PEG- EPS next Q-0.60 Inst Own83.80% Short Float5.95% Perf Quarter-59.76%
Sales140.70M P/S2.07 EPS this Y36.00% Inst Trans-2.33% Short Ratio6.51 Perf Half Y-63.97%
Book/sh0.88 P/B3.75 EPS next Y53.40% ROA-25.90% Target Price16.50 Perf Year-84.28%
Cash/sh2.81 P/C1.17 EPS next 5Y- ROE-70.90% 52W Range3.22 - 25.06 Perf YTD-60.38%
Dividend- P/FCF- EPS past 5Y20.80% ROI-41.30% 52W High-86.83% Beta3.48
Dividend %- Quick Ratio3.20 Sales past 5Y46.10% Gross Margin- 52W Low2.48% ATR0.36
Employees333 Current Ratio3.20 Sales Q/Q-73.70% Oper. Margin-60.40% RSI (14)28.43 Volatility9.71% 8.97%
OptionableYes Debt/Eq0.00 EPS Q/Q-58.60% Profit Margin-61.60% Rel Volume1.32 Prev Close3.57
ShortableYes LT Debt/Eq0.62 EarningsMay 04 BMO Payout- Avg Volume766.94K Price3.30
Recom2.00 SMA20-21.22% SMA50-42.90% SMA200-53.56% Volume1,009,819 Change-7.56%
Jul-23-21Downgrade Goldman Neutral → Sell $24 → $7
May-18-21Resumed Goldman Neutral $24
Mar-05-21Upgrade Chardan Capital Markets Neutral → Buy $30
Sep-18-20Downgrade Chardan Capital Markets Buy → Neutral $32.50 → $27.50
Aug-18-20Initiated Piper Sandler Overweight $40
Aug-11-20Upgrade Jefferies Hold → Buy $4 → $29
Aug-11-20Reiterated H.C. Wainwright Buy $8 → $41
Apr-30-19Initiated Jefferies Hold $7
Oct-22-18Initiated Chardan Capital Markets Buy $15
Oct-13-17Initiated Oppenheimer Outperform $19
Aug-04-17Reiterated H.C. Wainwright Buy $15 → $19
Feb-01-17Reiterated FBR & Co. Outperform $23 → $18
Aug-12-16Reiterated FBR Capital Outperform $43 → $23
Aug-01-16Reiterated H.C. Wainwright Buy $50 → $15
Aug-01-16Downgrade BofA/Merrill Buy → Neutral
Jul-29-16Resumed H.C. Wainwright Buy $50
Mar-30-16Initiated FBR Capital Outperform $40
Mar-03-16Initiated Guggenheim Buy
Jan-25-16Initiated H.C. Wainwright Buy $55
Oct-22-15Upgrade BofA/Merrill Neutral → Buy
May-23-22 08:00AM  
May-22-22 03:15PM  
May-10-22 07:00AM  
May-05-22 09:30AM  
May-04-22 08:25AM  
07:00AM  
Apr-28-22 07:00AM  
Apr-07-22 10:12AM  
Mar-22-22 12:47PM  
Mar-18-22 09:55AM  
07:00AM  
Mar-10-22 07:00AM  
Mar-03-22 07:00AM  
Mar-01-22 09:05AM  
07:00AM  
Feb-28-22 05:35PM  
09:00AM  
Feb-22-22 07:00AM  
07:00AM  
Feb-15-22 10:05AM  
Feb-08-22 07:00AM  
Feb-01-22 09:16AM  
Jan-24-22 07:00AM  
Jan-20-22 06:58AM  
Jan-19-22 05:01PM  
Jan-18-22 02:57PM  
Jan-04-22 07:00AM  
Dec-28-21 09:38AM  
Dec-21-21 09:38AM  
01:38AM  
Dec-16-21 09:38AM  
07:00AM  
Dec-08-21 09:38AM  
Nov-30-21 04:47PM  
07:00AM  
Nov-24-21 07:00AM  
Nov-11-21 06:32AM  
Nov-10-21 04:14PM  
08:15AM  
07:00AM  
02:00AM  
Nov-04-21 07:00AM  
Nov-01-21 03:01PM  
Oct-26-21 07:00AM  
Oct-18-21 12:26PM  
Oct-13-21 10:00AM  
Oct-02-21 01:15PM  
Sep-29-21 02:00PM  
Sep-15-21 03:35PM  
07:00AM  
Sep-07-21 07:00AM  
Aug-23-21 08:26AM  
Aug-05-21 07:00AM  
Aug-03-21 08:45AM  
07:00AM  
Jul-29-21 07:00AM  
Jul-28-21 01:51PM  
Jul-23-21 06:12AM  
Jul-22-21 11:51AM  
08:23AM  
07:33AM  
07:00AM  
05:26AM  
Jul-21-21 12:01PM  
Jul-20-21 03:02PM  
Jul-07-21 08:36AM  
Jul-02-21 01:45PM  
Jul-01-21 11:01AM  
07:00AM  
Jun-14-21 07:51PM  
Jun-10-21 07:00AM  
07:00AM  
Jun-04-21 02:30PM  
Jun-01-21 08:00AM  
May-25-21 08:00AM  
06:00AM  
01:33AM  
May-21-21 12:15PM  
May-20-21 08:00AM  
May-19-21 05:22PM  
09:01AM  
May-12-21 07:00AM  
May-11-21 08:00AM  
May-09-21 04:10AM  
May-04-21 08:20AM  
07:00AM  
06:45AM  
Apr-30-21 03:59PM  
Apr-28-21 07:00AM  
Apr-15-21 07:00AM  
Mar-30-21 09:30AM  
Mar-12-21 07:00AM  
Mar-08-21 07:00AM  
Mar-05-21 10:29AM  
Mar-02-21 08:15AM  
07:00AM  
07:00AM  
06:30AM  
Feb-26-21 08:00AM  
Feb-24-21 07:00AM  
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.